WeLeader Biomedical Co

WeLeader Biomedical Co Liabilities

The The Liabilities of WeLeader Biomedical Co (7713.TWO) as of Oct 21, 2026 is 1.19 B TWD. In the previous year, The Liabilities was 1.09 B TWD — a change of 9.11% (higher).

Liabilities

1.19 BTWD

YoY

9.11%

Last updated:

In 2025, WeLeader Biomedical Co's total liabilities amounted to 1.19 B TWD, a 9.11% difference from the 1.09 B TWD total liabilities in the previous year.

The WeLeader Biomedical Co Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2020
613.62 M TWD
Jan 1, 2021
525.68 M TWD
Jan 1, 2022
954.19 M TWD
Jan 1, 2023
881.78 M TWD
Jan 1, 2024
1.09 B TWD
Jan 1, 2025
1.19 B TWD
The WeLeader Biomedical Co Liabilities history
YEARLiabilitiesYoY
1.19 BTWD+9.11%
1.09 BTWD+23.57%
881.78 MTWD-7.59%
954.19 MTWD+81.52%
525.68 MTWD-14.33%
613.62 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

WeLeader Biomedical Co Stock analysis

What does WeLeader Biomedical Co do? WeLeader Biomedical Co Ltd generates revenue through the agency and trading of in vitro diagnostic instruments and reagent-related products, primarily serving domestic markets. The company provides distribution, after-sales, and maintenance services for laboratory reagents, consumables, instruments, and equipment, alongside construction planning for medical testing laboratories. Additional services include equipment procurement, operational coaching, human resources training, and digital medical examination platforms. Domestic clients purchase these integrated solutions for healthcare facilities and laboratories. The firm's product portfolio focuses on medical testing-related services, including operational coaching and digital platform solutions, which are sold to healthcare institutions requiring comprehensive laboratory support. Distribution of in vitro diagnostic instruments and reagents forms a core revenue stream, supported by ancillary services like equipment procurement and site construction planning. These offerings target domestic healthcare providers seeking efficient laboratory management solutions. WeLeader Biomedical Co Ltd's business model combines product sales with service delivery, emphasizing domestic market penetration. The company's revenue is derived from both the sale of diagnostic instruments and reagents and the provision of specialized services such as operational coaching and digital platform access. Healthcare institutions and laboratories are the primary buyers of these integrated offerings, leveraging the company's expertise in laboratory construction and equipment maintenance. WeLeader Biomedical Co is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing WeLeader Biomedical Co's Liabilities

WeLeader Biomedical Co's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating WeLeader Biomedical Co's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing WeLeader Biomedical Co's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

WeLeader Biomedical Co's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in WeLeader Biomedical Co’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about WeLeader Biomedical Co stock

The Liabilities of WeLeader Biomedical Co is 1.19 B TWD in 2025.

The Liabilities of WeLeader Biomedical Co changed from 1.09 B TWD to 1.19 B TWD, representing a 9.11% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities WeLeader Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's WeLeader Biomedical Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — WeLeader Biomedical Co

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — WeLeader Biomedical Co